Molnumize 200mg Capsule is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.Molnumize 200mg Capsule is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use.Molnumize 200mg Capsule should be taken orally for no longer than 5 consecutive days. It is important to complete the entire 5 days of treatment, therefore do not stop taking it even if you feel better. The medicine may cause dizziness, headache, diarrhea, and nausea in some patients. If one experiences any such side effects, discuss them with the doctor. They may help with the treatment or suggest ways to prevent them.Before taking Molnumize 200mg Capsule, let the doctor know if you have any pre-existing medical conditions. To make sure it is safe for you, inform your doctor about all the other medications you are taking. The use of Molnumize 200mg Capsule is not recommended in pregnant women. Pregnant and breastfeeding women should consult with their doctors before taking this medicine.
Salts
More details
Alcohol:
It is not known whether it is safe to consume alcohol with Molnumize 200mg Capsule. Please consult your doctor.
Pregnancy:
Molnumize 200mg Capsule may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Breastfeeding:
Molnumize 200mg Capsule is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Driving:
It is not known whether Molnumize 200mg Capsule alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Kidney:
Molnumize 200mg Capsule is safe to use in patients with kidney disease. No dose adjustment of Molnumize 200mg Capsule is recommended.
Liver:
Molnumize 200mg Capsule is safe to use in patients with liver disease. No dose adjustment of Molnumize 200mg Capsule is recommended.
Torrent Pharmaceuticals Ltd
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if youΓ’ΒΒre worried about them
Common Side Effects :
Nausea
Dizziness
Diarrhea
